



SIMULTANEOUS ESTIMATION OF BEPOTASTINE BESILATE AND BENZALKONIUM CHLORIDE 
IN OPHTHALMIC FORMULATION BY RP-HPLC METHOD 
Original Article 
 
KRISHNA R. GUPTAa*, SONALI S. ASKARKARa 
aDepartment of Pharmaceutical Chemistry, Smt Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur, Maharashtra, India 
Email: krg1903@gmail.com   
 Received: 27 Feb 2016 Revised and Accepted: 20 Apr 2016 
ABSTRACT 
Objective: Development and validation of stability indicating RP-HPLC method for the simultaneous determination of bepotastine besilate (Bepo B) 
and benzalkonium chloride (BKC) in an ophthalmic dosage form. 
Methods: A chromatographic separation of the drug, as well as a preservative, was achieved using Shimadzu HPLC 1100 series consisted of binary 
pump LC-10 ADvp, Rheodyne universal injector 7725i and Shimadzu SPD-10 UV–Visible detector. The chromatographic separations were 
performed using Analytical® Hyperchrome ODS C18, 5 μm, 250 mm X 4.6 mm i.d. column with isocratic mobile phase Acetonitrile: phosphate buffer 
(60:40) pH 5.5. The drug and a preservative were monitored at an ambient temperature and detection wavelength of 210 nm with a flow rate of 1 
ml/min and an injection volume of 20 µl.  
Results: The mean % recovery at the 80, 100 and 120% level for Bepotastine and benzalkonium chloride was found to be 100.09 and 100.81% 
respectively and % RSD was found to be 0.21 and 0.85% respectively, which meets the established acceptance criteria. Forced degradation of 
bepotastine besilate was carried under alkaline, acidic, neutral, oxidative, humidity, thermal and photodegradation conditions and it was analyzed 
by proposed method. The drug degrades to some extent in all forced degradation condition.  
Conclusion: The developed method was validated as per ICH guidelines using validation parameters such as accuracy, precision, linearity and 
range, robustness, ruggedness, LOD, LOQ, specificity, and system suitability testing. The proposed method can be used for routine analysis stability 
testing and assay of bepotastine besilate ophthalmic solution in quality control laboratories. 
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INTRODUCTION 
Bepotastine besilate (Bepo B) is a selective histamine H1-receptor 
antagonist. Bepreve™ (bepotastine besilate ophthalmic solution), 
1.5% is a sterile ophthalmic solution of bepotastine besilate 
proposed for the treatment of itching associated with signs and 
symptoms of allergic conjunctivitis in patients aged 3 y or older. The 
proposed dosage and route of administration for Bepreve™ 
(bepotastine besilate ophthalmic solution), 1.5% is as follows: instill 
one drop into the affected eye(s) twice a day (BID). Bepotastine 
besilate (also known as TAU-284 and SNJ1773) was originally 
developed in Japan by Ube Industries, Ltd. and Tanabe Seiyaku Co., 
Ltd. as a treatment for allergic rhinitis. An oral preparation of 
bepotastine besilate (Talion® tablets, Mitsubishi Tanabe Pharma 
Corporation [formerly Tanabe Seiyaku Company, Ltd.]) was approved 
in Japan in July 2000 and launched in October 2000. In January 2002, 
the additional indication of pruritus/itching accompanying urticaria 
and other skin diseases was approved in Japan [1-2]. 
A clinical trial study showed that bepotastine, cetirizine, 
fexofenadine, and olopatadine inhibit the histamine-induced wheal-
and-flare response of humans in vivo and induce a variable systemic 
sedative effect and impaired psychomotor activity [3]. Bepotastine 
was generally well tolerated in adult and paediatric patients with 
Allergic conditions. It was also noticed that bepotastine (20 mg/day) 
was significantly more effective than terfenadine (120 mg/day) in 
patients with perennial allergic rhinitis. Although a number of 
studies have been made to evaluate clinical efficacy and safety of 
bepotastine, scarcely any literature is available for its estimation [4]. 
Bepotastine besilate (Bepo B) chemically known as ({d-(S)-4-[4-[(4-
chlorophenyl) (2-pyridyl) methoxy] piperidino} butyric acid 
monobenzene sulphonate), is a new second-generation 
antihistamine developed in Japan. It reduces the natural chemical 
histamine in the body which can produce allergic symptoms of 
itching or watery eyes. The chemical structure of bepotastine 
besilate is depicted in fig. 1. 
 
Fig. 1: Structure of bepotastine besilate 
 
Benzalkonium chloride (BKC), a typical quaternary ammonium salt, 
is often used as an antiseptic. Its structure is shown in fig. 2, and the 
C12 homolog is the major species in a benzalkonium chloride 
preparation [5]. The mode of antiseptic action of quaternary 
ammonium compounds appears to be associated with their effect on 
the cytoplasmic membrane that controls cell permeability, and the 
C12 homolog is most effective against yeast and fungi [6]. 
 
 
Fig. 2: Structure of benzalkonium chloride 
 
A literature survey reveals that Mamta D et al.,[7] developed LC-
MS/MS method for estimation of bepotastine besilate. Sharath P et 
al.,[8] developed RP-HPLC method for estimation of Bepotastine 
Besilate only. Narasimha K et al.,[9] has given stability indicating 
HPLC method for the quantification of bepotastine besilate and its 
related substances. It is necessary to estimate % purity of drug as 
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well as a preservative in an ophthalmic formulation, hence it was 
thought worthwhile to develop and validate the stability indicating 
HPLC method for simultaneous estimation of bepotastine besilate 
and benzalkonium chloride.  
Literature survey revealed that separate chromatographic conditions 
have been used for determination of drug and preservative in 
ophthalmic dosage forms. So, it was thought worthwhile to develop a 
method in which both drug and preservative content can be 
determined in the same chromatographic condition. 
MATERIALS AND METHODS 
Chemicals 
API (bepotastine besilate-100.4% purity) was supplied by Bal 
Pharma Ltd. Bommasandra Industrial area, Bangalore, India. 
Bepotastine besilate ophthalmic solution 1.5% is available under the 
brand name BepreveTM by ISTA Pharmaceuticals, Inc. Irvine, CA. 
Methanol; Acetonitrile (HPLC grade) was obtained from Finar 
Limited, Ahmadabad, India. Furthermore, Triethylamine (HPLC 
grade) procured from Himedia Laboratories, Mumbai, India. 
Potassium dihydrogen phosphate, sodium hydroxide, hydrochloric 
acid and hydrogen peroxide (AR grade) obtained from Qualigens 
Fine Chemicals, Mumbai, India. 
Chromatographic condition and equipment 
The HPLC system consisted of Shimadzu HPLC 1100 series consisted 
of binary pump 
LC-10 ADvp, Rheodyne universal injector 7725i and Shimadzu SPD-
10 UV–Visible detector. The chromatographic separations were 
performed using Analytical® Hyperchrome ODS C18, 5 μm, 250 mm 
X 4.6 mm i.d. column, at ambient temperature, eluted with mobile 
phase at the flow rate of 1.0 ml/min. The mobile phase consisted of 
acetonitrile and potassium dihydrogen phosphate buffer (60:40, 
v/v), apparent pH adjusted to 5.5±0.1 with phosphoric acid solution, 
filtered through 0.45 μm nylon filter and degassed in ultrasonic bath 
prior to use. Wavelength was selected by scanning standard 
solutions of both drugs over 200 to 400 nm wavelengths using 
Shimadzu model 1601 double beam UV–visible spectrophotometer 
with a pair of 10 mm matched quartz cells. Measurements were 
made with injection volume 20 μL and ultraviolet (UV) detection at 
210 nm, as both components show a reasonable good response at 
this wavelength. 
Optimized chromatographic conditions 
Column-Analytical® Hyperchrome ODS C18, 5 μm, 250 mm X 4.6 mm 
Mobile Phase-Acetonitrile and KH2PO4 buffer, pH 5.5 (60:40 v/v) 
Detection Wavelength-210 nm 
Flow rate-1.0 ml/min 
Temperature: Ambient-28-30 °C 
Injection volume-20 ml  
Preparation of solutions 
Standard stock solution of bepotastine besilate 
A Standard stock solution of bepotastine Besilate (0.5 mg/ml) was 
prepared by dissolving 12.5 mg of bepotastine besilate in 25 ml 
mobile phase. 
Standard stock solution of benzalkonium chloride  
A Standard stock solution of benzalkonium chloride (1 mg/ml) was 
prepared by dissolving 25 mg of benzalkonium chloride in 25 ml 
mobile phase. 
Pharmaceutical dosage form solution 
2.5 ml of pharmaceutical dosage form was transferred to 50 ml 
volumetric flask spiked with 5 ml of benzalkonium chloride (1 
mg/ml) about 30 ml of mobile phase was added and sonicated for 20 
min. The volume was completed to the mark with mobile phase to 
obtain a sample stock solution of 1500 µg/ml bepotastine Besilate 
and 210 µg/ml of benzalkonium chloride. 
Concentrations ranging from 50-200 µg/ml for bepotastine Besilate 
and 10-100 µg/ml for benzalkonium chloride were prepared from 
stock solution and different validation parameters were performed. 
Buffer preparation 
Phosphate buffer was prepared by dissolving 1.36 gm of potassium 
dihydrogen phosphate in 400 ml double distilled water 0.5 ml 
triethylamine was added to it and pH was make up to 5.5 using 
dilute orthophosphoric acid, and final volume was made up to 500 
ml with double distilled water. 
Validation procedure 
Validation of the newly developed method was studied in terms of 
accuracy, precision, linearity and range, robustness, ruggedness, 
limit of detection (LOD), limit of quantitation (LOQ), specificity and 
system suitability testing as per ICH guidelines [10]. 
System suitability study was done to check the performance of the 
system and the response after replicate injection of the standard 
solution. The chromatogram of standard bepotastine, std 
benzalkonium chloride and mix standard are shown in fig. 3-5. 
 
 
Fig. 3: Chromatogram of STD bepotastine besilate 
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Fig. 4: Chromatogram of mixed standard bepotastine basilate and benzalkonium chloride 
 
 
Fig. 5: Chromatogram of standard benzalkonium chloride 
 
The accuracy of the method was determined by calculating percentage 
recoveries of bepotastine and benzalkonium chloride respectively by 
standard addition method. A known amount of standard solution of 
Bepotastine (60, 90 and 120 µg/ml) was added to sample solution of 
Bepotastine (60µg/ml). Similarly, a known amount of standard solution 
of benzalkonium chloride (16, 20 and 24 µg/ml) was added to sample 
solution of benzalkonium chloride (1 µg/ml). The precision of the 
method was studied by checking repeatability, interday and intraday 
precision for single concentration thrice.  For linearity and range the 
solutions were prepared from a stock solution of bepotastine 
Besilate (500 µg/ml) ranging from 50-200 µg/ml and from a stock 
solution of benzalkonium chloride (1000 µg/ml) ranging from 10-
100 µg/ml, the calibration curve was generated, and regression 
parameters were obtained. 
Robustness of the method was studied by changing the flow rate 
by±0.2 ml/min, change in wavelength by±5 units, change in pH 
by±0.2 units and change in mobile phase composition. The changes 
in the response of bepotastine were noted and compared with the 
normal condition. 
Specificity: forced degradation studies 
Forced degradation of drug product was carried out under 
thermolytic, relative humidity, acid/base hydrolytic and oxidative 
stress conditions. Thermal and relative humidity degradation of the 
standard drug were carried out in the solid state. After the 
degradation stock solutions were prepared by dissolving in the 
mobile phase. From these solutions, aliquots were diluted with 
mobile phase to achieve a concentration of 150 μg/ml of bepotastine 
besilate and 21 μg/ml of benzalkonium chloride based on the 
labeled strength. For thermal stress, samples of drug substances and 
drug product were placed in a controlled temperature oven at 60 °C 
for 3 hr. Acid hydrolysis of drug substance and drug product in 
solution state was conducted with 0.1 N hydrochloric acid at 50 °C 
for 3 hr. Base hydrolysis of drug product was conducted by 1N 
sodium hydroxide solution at 50 °C for 3 hr. For oxidative stress, 
sample solutions of a drug product in 3% hydrogen peroxide were 
kept at 50 °C for 3 hr. The humidity effect was carried in the solid 
state, kept at 75% RH at ambient temperature for 48 h. 
RESULTS  
System suitability study 
System suitability parameters recorded during the experimentation 
are shown in table 1.  
Accuracy 
The accuracy of the method was determined for bepotastine besilate 
and benzalkonium chloride by spiking its stock solution in a blank 
matrix in triplicate at levels 80, 100, 120% of the specified limit. The 
mean % recovery at the 80, 100 and 120% level for Bepotastine and 
benzalkonium chloride was found to be 100.09 and 100.81% 
respectively and % RSD was found to be 0.21 and 0.85% 
respectively, which meets the established acceptance criteria. Thus, 
the study proves that the method is accurate in the considered range 
(table 2 and 3). 
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Table 1: Observation of system suitability parameter 
S. No. AUC of BKC AUC of Bepo B 
1. 20.086 2451.739 
2. 19.983 2450.697 
3. 20.134 2452.042 
4. 20.010 2451.686 
5. 20.045 2450.304 
Mean 20.051 2451.2936 
±SD 0.0596 0.7496 
%RSD 0.30 0.03 
Theoretical plate per column 5941 3139 
Retention Time 4.040 5.467 
Resolution  - 4.665 
Asymmetry 1.268 1.628 
 
Table 2: Result of recovery study for bepotastine 














80% 1 ml~ 60µg/ml 1961.112  60  60.0 100.0 100.1±0.1 0.1% 
1952.739 60 60.07 100.1 
1970.013 60 60.09 100.2 
100% 2453.101 90 89.60 99.56 99.88±0.2872 0.29% 
2459.139 90 90.03 100.0 
2460.489 90 90.12 100.1 
120% 2942.106 120 120.40 100.3 100.3±0.3 0.30% 
2930.897 120 120.12 100.1 
2963.784 120 120.56 100.5 
Mean 100.09 0.21% 
 
Table 3: Result of recovery study for benzalkonium chloride 














80% 2.5 ml~1µg/ml 17.124 16 16.07 100.4 100.4±0.4 0.40% 
17.322 16 16.12 100.8 
17.017 16 16.01 100.0 
100% 21.105 20 20.32 101.6 101.8±1.5099 1.48% 
21.830 20 20.67 103.4 
21.009 20 20.08 100.4 
120% 25.197 24 24.16 100.7 100.25±0.3931 0.39% 
24.996 24 23.99 99.96 
25.268 24 24.27 100.1 
Mean 100.81 0.85% 
 
Specificity 
The forced degradation studies were performed to check the 
possible degradation of an active pharmaceutical ingredient when 
exposed to various conditions such as acidity, alkalinity, oxidative, 
neutral and thermal conditions.  
The analytical method was used to measure the analyte response in the 
presence of its degradation products. The degradation results for all 
stress conditions are discussed (table 4). The overlain chromatograms of 
various stress conditions are shown in fig. 6a-i respectively. 
Assay 
Analysis of samples of marketed bepotastine besilate ophthalmic 
solution containing 1.5% bepotastine besilate was carried out, the 
chromatogram of formulation recorded is shown in fig. 7. % Assay 
for Bepo B and BKC was found to be 100.50 and 51.648% 
respectively. (table 5). 
Precision 
The precision of the proposed method was determined by carrying 
out repeatability and intermediate studies.  
 
Table 4: Summary of stability testing 
S. No. Stressed condition % degraded drug 
Bepo B Std exposed Bepo B eye drop exposed 
1 1N NaOH 5.640±0.02 33.70±0.11 
2 0.5N NaOH 2.22±0.13 27.15±0.34 
3 1N HCl 10.56±0.08 21.92±0.21 
4 0.5 N HCl 7.60±0.32 20.65±0.36 
5 Neutral 2.00±0.11 12.09±0.51 
6 3%H2O2 0.00 11.27±0.43 
7 Humidity (40 °C/75%RH) 7.08±0.19 2.29±0.28 
8 UV light 7.86±0.36 10.27±0.53 
9 60oC Dry heat 10.44±0.29 0.00 
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Fig. 6a: 1 N NaOH 
 
 
Fig. 6b: 0.5 N NaOH 
 
 
Fig. 6c: 1 N HCl 
 
 
Fig. 6d: 0.5 N HCl 
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Fig. 6e: Neutral condition 
 
 
Fig. 6f: 3% H2O2 
 
 
Fig. 6g: Humidity (40 °C/75% RH) 
 
 
Fig. 6h: UV light 
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Fig. 6i: 60 °C dry heat 
Fig. 6a-i: Overlain chromatogram of standard and sample under Stressed conditions 
 
 
Fig. 7: Chromatogram of Bepotastine Basilate ophthalmic formulation 
 
Table 5: Results of estimation in marketed formulation 
S. No. Amt. of formulation taken 
(mL) 
Detector response (peak area) % Label claim 
 Bepo B STD BKC 
STD 
Bepo B Sample BKC 
Sample 
Bepo B BKC 
 
1 ~2.5 ml   2480.476 21.107 101.2 51.82 
2   2490.760 21.113 101.6 51.20 
3 2451.739 20.086 2454.562 21.105 100.1 51.82 
4   2452.145 21.132 100.0 52.00 
5   2443.917 21.120 99.63 51.40 
Mean 100.50 51.648 
±SD 0.8465 0.333 
%RSD 0.84 0.65 
 
The repeatability was checked by repeatedly (n=5) injecting sample 
solutions and computing the relative standard deviation (%RSD) of 
the assay results. The % RSD observed was 0.84% for Bepo B and 
0.65% for BKC, which was well within the acceptance criteria and the 
study concludes repeatability of the method. The method precision 
was repeated on different days, by a different analyst. The SD was 
calculated and found to be 0.15, 0.85 and 0.99 respectively which was 
within the limit. Hence, the method is precise and rugged. (table 6). 
 
Table 6: Results of intermediate precision 
Parameters Mean % label claim±SD of bepotastine 
Different Analyst (n=3) 100.38±0.15 
Intraday variation (n=5) 99.99±0.85 
Interday variation (n=5) 98.71±0.99 
 
LOD and LOQ 
LOD and LOQ were estimated from the calibration curve for Bepo B 
was found to be 0.05430 µg/ml and 0.01646µg/ml respectively.  
LOD and LOQ were calculated by using formula LOD = 3.3 × N/B 
and LOQ = 10 × N/B were used, where N is the standard 
deviation of the response and B is the slope of the corresponding 
calibration curve.  
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To prove the reliability of the analytical method during the normal 
usage, some small but deliberate changes were made in the 
analytical method. The robustness of the method was studied by 
changing the flow rate (0.8, 1.2 ml/min), wavelength (215 and 205 
nm), pH (5.3 and 5.7) and mobile phase composition, the retention 
time, theoretical plates, asymmetry factor were observed. 
Theoretical plates and asymmetry values were found well within 
acceptance criteria. Thus, the study proves the reliability of the test 
method for minor changes under chromatographic conditions. 
Hence, the method can be termed as robust. (table VII). 
 
Table 7: Observation and results of robustness study 
S. No. Deliberate changes RT Asymmetry Theoretical Plates 
1 Standard condition 5.467 1.628 3139 
2 Change in flow rate (0.8 ml/min) 6.563 1.529 3623 
3 Change in flow rate (1.2 ml/min) 4.513 1.256 3126 
4  Change in pH (5.3) 5.491 1.367 3089 
5 Change in pH (5.7) 5.376 1.561 3156 
6 Change in wavelength (215 nm) 5.477 1.444 3331 
7 Change in wavelength (205 nm) 5.457 1.485 3211 
8 Change in mobile phase(55:45) 5.404 1.315 3132 
9 Change in mobile phase(65:35) 5.412 1.232 3069 
CV 0.0944 0.0915 0.0541 
Overall CV 0.0800 
 
Table 8: Statistical comparison of the results obtained by applying the proposed HPLC method for determination of bepotastine Besilate 
and benzalkonium chloride simultaneously and the reported HPLC method for determination of bepotastine besilate in bulk drug and 
ophthalmic formulation 
Items HPLC method for estimation of Bepotastine and Benzalkonium 
chloride 
Reported method (only for estimation of Bepo 
B) 
Bepo B BKC Bepo B 
Mean 100.50 51.648 98.70 
% RSD 0.84 0.65 ND 
N 5 5 5 
Students' t-test 4.735 (5.893)*   
F-value 1.244 (4.21)**   
fig. between parenthesis represent the corresponding tabulated value of t at P=0.001, ** fig. between parenthesis represent the corresponding 
tabulated value of F at P=0.05 
 
Linearity and range 
Accurately weighed quantities equivalent to 80, 90, 100, 110 and 
120% of label claim (bepotastine besilate) were taken and dilutions 
were made as described under marketed formulation. Then, each 
solution was injected and chromatograms were recorded. The 
correlation coefficient was found to be of Bepotastine 0.9993 and 
0.9982 for BKC. 
DISCUSSION 
The main aim of the chromatographic method was to separate 
bepotastine Besilate and benzalkonium chloride in a single 
mobile phase with similar chromatographic conditions. Sharath 
et al.,[8] revealed that separate chromatographic conditions 
were used for estimation of drug and benzalkonium chloride 
specifically in the ophthalmic formulation. Previously methanol: 
buffer system was used as a mobile phase, but benzalkonium 
chloride cannot be resolved from bepotastine. Similarly, when 
ACN: Buffer system has used both bepotastine as well as 
benzalkonium chloride having theoretical plates 3139 and 5941 
respectively, with the resolution of 4.665. 
Hence, The objective of the study to develop and validate the 
stability indicating HPLC method for simultaneous estimation of 
Bepo B and BKC was accomplished by using Analytical® 
Hyperchrome ODS C18, 5 μm, 250 mm X 4.6 mm i.d. column, flow 
rate 1 ml/min, mobile phase Acetonitrile: buffer (60:40 v/v) was 
found to be giving better resolution. % RSD for accuracy study 
for Bepo B and BKC was found to be 0.21 and 0.85% 
respectively, which meets the established acceptance criteria. 
The % RSD for the precision study was found to be 0.84% for 
Bepo B and 0.65% for BKC. % RSD for Intermediate precision 
study was found to be 0.66% which is within specified limits 
hence it can be said that the method is precise. Theoretical 
plates and asymmetry values were found well within acceptance 
criteria in robustness. From the specificity study it can be said 
that standard bepotastine besilate is soft susceptible to 
degradation as degradation is below 15% and no relevant 
degradation product is observed and bepotastine besilate eye 
drop is overdone susceptible to degradation as degradation is 
above 15% in acidic and alkaline condition.  
Unknown impurity was found at RRT 0.9093 in the acidic and 
alkaline condition which does not match with the reported 
impurities given by Narasimha R. K. et al., [9] which may be 
generated because of excipients present in the formulation. 
CONCLUSION 
The proposed method was found to be simple, precise, accurate 
and rapid for determination of Bepo B and BKC from pure and its 
ophthalmic dosage forms. The sample recovery in a formulation 
was in good agreement with their respective label claims and they 
suggested non-interference of formulation excipients in the 
estimation. Hence, this method can be easily and conveniently 
adopted for routine analysis of Bepo B in pure and its dosage 
forms. 
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